New Zealand vs Oman: Tuberculosis patients who tested positive for HIV
New Zealand
3 patients
in 2021
Oman
4 patients
in 2021
New Zealand rank
134th
Oman rank
131st
Tuberculosis patients who tested positive for HIV over time
- New Zealand
- Oman
How they compare
Oman currently reports 4 patients against 3 patients in New Zealand, a difference of 1 patients.
That makes Oman's figure about 1.3 times New Zealand's.
The two have swapped places 2 times across 19 shared years of data; in 2003 it was Oman ahead.
New Zealand ranks 134th and Oman ranks 131st of 201 countries.
Oman has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | New Zealand | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 6.43 patients | 9.57 patients | 3.14 patients | Oman |
| 2010s | 1.8 patients | 6.9 patients | 5.1 patients | Oman |
| 2020s | 2.5 patients | 6 patients | 3.5 patients | Oman |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients who tested positive for hiv, New Zealand or Oman?
- Oman, at 4 patients against 3 patients in New Zealand as of 2021.
- What is the difference in tuberculosis patients who tested positive for hiv between New Zealand and Oman?
- 1 patients, with Oman ahead.
- How many years of comparable data are there for New Zealand and Oman?
- 19 years are reported by both, from 2003 to 2021.
- How do New Zealand and Oman rank globally for tuberculosis patients who tested positive for hiv?
- New Zealand ranks 134th and Oman ranks 131st of 201 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients who tested positive for HIV. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of tuberculosis (new and relapsed) patients that tested positive for HIV.